Previous close | 5.82 |
Open | 5.77 |
Bid | 8.30 |
Ask | 10.10 |
Strike | 16.00 |
Expiry date | 2024-11-15 |
Day's range | 5.77 - 5.90 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Shattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia indications for lead candidate SL-172154, following encouraging interim data from the phase IB dose expansion study.
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.